Document text
Principal Investigator: EDWARD CHU
Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE
Fiscal Year: 2022
Award: $334,913
Funding agency: National Cancer Institute
Abstract It is now well-established that COVID-19 in patients with cancer carries a higher morbidity and mortality, especially in amongst patients with hematologic malignancies1, 2. Effective vaccines have been developed and authorized by the FDA to combat this pandemic3-5. However, emerging data suggests that despite these vaccines inducing high levels of immunity in the general population, patients with hematologic malignancies have lower rates of seroconversion for the SARS-CoV-2 Spike antibody6-9. Indeed, our prior data had suggested excellent immunogenicity of the currently FDA authorized Covid-19 vaccines for most patients with a malignant diagnosis with exception of unique cohorts- patients with hematological malignancies and following highly immune suppressive therapies (SCT, CAR-T, anti-CD20). Our current study plans to address the efficacy of Covid-19 booster vaccinations amongst patients with a cancer diagnosis with a special focus on patients with undetectable or low anti-Spike IgG antibody levels. 250 patients with a diverse range of ethnicities, cancer diagnosis and prior cancer therapies will be enrolled in this study and the response to booster vaccinations will be assessed using standard anti-Spike IgG as well as investigational T cell and Virus Neutralization assays. In addition, in a second cohort we will define if a “mix and match” vaccination strategy might be more successful at achieving detectable immunity in patients with persistently negative/low antibody levels despite booster vaccinations. In this cohort, 100 patients will be accrued who by anti-spike IgG assays have not developed detectable or have low levels of humoral immunity. These patients will be randomized to receive an additional dose of an mRNA based vaccine (BNT162b2) versus an adenoviral vaccine (AdCov2.S). Both studies will assess safety and efficacy of these vaccination schemes and will provide long-term data with 24 months of follow up planned. These studies should provide critical information to best address proper protective strategies for uniquely vulnerable patient populations with a cancer diagnosis.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><AECC><Active Follow-up><Address><Affect><Aging><Albert Einstein Cancer Center><Antibodies><Assay><BNT 162b2><BNT162b2><Bioassay><Biologic Assays><Biological Assay><Biology><Booster Immunization><CCSG><COVID-19><COVID-19 booster><COVID-19 vaccine><COVID-19 vaccine booster><COVID-19 virus><COVID19><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancer Burden><Cancer Cause><Cancer Center><Cancer Center Support Grant><Cancer Etiology><Cancer Treatment><Cancers><Catchment Area><Center for Cancer Research><Chromatin><Clinical><Clinical Informatics><CoV-2><CoV2><Colo-rectal Cancer><Colon Cancer><Colon Carcinoma><Colorectal Cancer><Community Outreach><Data><Development><Diagnosis><Diagnostic><Dose><Education and Outreach><Effectiveness><Enrollment><Epidemiologic Research><Epidemiologic Studies><Epidemiological Studies><Epidemiology Research><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Ethnic Origin><Ethnicity><Evolution><Experimental Therapies><Funding><Gene Transcription><General Population><General Public><Genetic><Genetic Transcription><Health system><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematology><Hematopoietic Cancer><Home><Hormonal><Human><Humoral Immunities><IgG><Imaging technology><Immune><Immunes><Immunity><Immunoglobulin G><Immunotherapeutic agent><Instruction and Outreach><Intestinal><Intestines><Investigation><Investigational Therapies><Investigational Treatments><Investigators><Malignant><Malignant - descriptor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Medicine><Metabolic><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Minority><Minority Groups><Minority People><Minority Population><Minority individual><Modern Man><Morbidity><Morbidity - disease rate><NCI Center for Cancer Research><National Cancer Burden><Neoplasm Metastasis><Normal Cell><Obesity><Pathogenesis><Patients><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Population Research><Population-based research><Population-level research><Preventative strategy><Prevention><Prevention program><Prevention strategy><Preventive strategy><Progenitor Cells><Provider><RNA Expression><RNA vaccine><RNA-based vaccine><Randomized><Research><Research Activity><Research Personnel><Research Resources><Researchers><Resource Sharing><Resources><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 booster><SARS-CoV-2 vaccine><SARS-CoV-2 vaccine booster><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Scheme><Science><Secondary Immunization><Secondary Neoplasm><Secondary Tumor><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><T-Cells><T-Lymphocyte><Technology><Therapeutic Studies><Therapeutic Trials><Therapy Research><Training and Outreach><Transcription><Translating><Translations><Tutoring and Outreach><Vaccination><Vaccines><Villus><Virus><Wuhan coronavirus><active followup><adiposity><anti-CD20><anti-cancer therapy><antibody-based immunity><anticancer therapy><booster against COVID-19><booster against SARS-CoV-2><booster vaccination><bowel><cancer care><cancer cell><cancer diagnosis><cancer disparity><cancer epidemiology><cancer health disparity><cancer in the colon><cancer metastasis><cancer microenvironment><cancer prevention><cancer progression><cancer therapy><cancer-directed therapy><cancer-related health disparity><cohort><combat><community engagement><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><corpulence><developmental><dietary><disparity in cancer><enroll><epidemiologic investigation><epidemiology study><experimental therapeutic agents><experimental therapeutics><follow up><follow-up><followed up><followup><hCoV19><human cancer mouse model><human stem cells><immune drugs><immune-based therapeutics><immunization strategy><immunogenicity><immunologic preparation><immunologic therapeutics><immunotherapeutics><immunotherapy agent><innovate><innovation><innovative><mRNA vaccine><mRNA-based vaccine><malignancy><microbiome><mortality><mouse model><murine model><nCoV2><neoplasm progression><neoplasm/cancer><neoplastic progression><novel><patient population><pre-clinical><pre-clinical study><preclinical><preclinical study><programs><randomisation><randomization><randomly assigned><response><seroconversion><small molecule inhibitor><social role><socio-economic><socio-economically><socioeconomically><socioeconomics><stem cell differentiation><stem cells><study characteristics><thymus derived lymphocyte><tumor cell metastasis><tumor microenvironment><tumor progression><vaccination strategy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus>